1
|
Kriner P, Severus E, Korbmacher J, Mußmann L, Seemueller F. Lithium prescription trends in psychiatric inpatient care 2014 to 2021: data from a Bavarian drug surveillance project. Int J Bipolar Disord 2023; 11:40. [PMID: 38112925 PMCID: PMC10730486 DOI: 10.1186/s40345-023-00323-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/19/2023] [Accepted: 12/04/2023] [Indexed: 12/21/2023] Open
Abstract
OBJECTIVES Lithium (Li) remains one of the most valuable treatment options for mood disorders. However, current knowledge about prescription practices in Germany is limited. The objective of this study is to estimate the prevalence of current Li use over time and in selected diagnoses, highlighting clinically relevant aspects such as prescription rates in elderly patients, concomitant medications, important drug-drug interactions, and serious adverse events. METHODS We conducted a descriptive analysis of Li prescriptions, analyzing data from the ongoing Bavarian multicenter drug safety project Pharmaco-Epidemiology and Vigilance (Pharmako-EpiVig) from the years 2014-2021. Our study included 97,422 inpatients, 4543 of whom were prescribed Li. RESULTS The Li prescription rate in unipolar depression (UD) remained constant at 4.6% over the observational period. In bipolar disorder (BD), the prescription rate increased significantly from 28.8% in 2014 to 34.4% in 2019. Furthermore, 30.3% of patients with Li prescriptions did not have a diagnosis of BD or UD, and 15.3% of patients with schizoaffective disorder were prescribed Li. The majority (64%) of patients with Li prescriptions were prescribed five or more drugs. Most of the 178 high-priority drug-drug interactions were due to hydrochlorothiazide (N = 157) followed by olmesartan (N = 16). CONCLUSION Our study does not substantiate concerns about a decline in Li prescription. The decline in prescription rates observed in some diagnostic groups in 2020 and 2021 may be associated with the COVID-19 pandemic. The symptom-oriented use of Li beyond BD and UD is common. Polypharmacy and drug-drug interactions present a challenge in Li therapy. Old age and comorbid substance use disorder do not appear to be major deterrents for clinicians to initiate Li therapy.
Collapse
Affiliation(s)
- Paul Kriner
- Kbo-Lech-Mangfall-Klinik Garmisch-Partenkirchen, Auenstrasse 6, 82467, Garmisch-Partenkirchen, Germany.
| | - Emanuel Severus
- Asklepios Klinik Nord Psychiatrie Ochsenzoll, Langenhorner Chaussee 560, 22419, Hamburg, Germany
| | - Julie Korbmacher
- Bayerisches Institut Für Daten, Analysen Und Qualitätssicherung, Am Moosfeld 13, 81829, Munich, Germany
| | - Lisa Mußmann
- Bayerisches Institut Für Daten, Analysen Und Qualitätssicherung, Am Moosfeld 13, 81829, Munich, Germany
| | - Florian Seemueller
- Kbo-Lech-Mangfall-Klinik Garmisch-Partenkirchen, Auenstrasse 6, 82467, Garmisch-Partenkirchen, Germany
- Department of Psychiatry and Psychotherapy Nussbaumstrasse 7, Ludwig-Maximilians-Universität, 80336, Munich, Germany
| |
Collapse
|
2
|
Mahaisavariya C, Vanitcharoenkul E, Kitcharanant N, Chotiyarnwong P, Unnanuntana A. Exploring the osteoporosis treatment gap after fragility hip fracture at a Tertiary University Medical Center in Thailand. BMC Geriatr 2023; 23:70. [PMID: 36737708 PMCID: PMC9898992 DOI: 10.1186/s12877-023-03778-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/21/2022] [Accepted: 01/27/2023] [Indexed: 02/05/2023] Open
Abstract
BACKGROUND (1) To evaluate the prescription rate of anti-osteoporosis medication, and (2) to identify factors associated with patients not receiving anti-osteoporosis medication or, when prescribed, not persisting with medication 1 year after hip fracture treatment. METHODS We retrospectively reviewed the medical records of all fragility hip fracture patients admitted to the orthopedic unit of the Faculty of Medicine Siriraj Hospital, Mahidol University, between July 1, 2016, and December 31, 2019. We identified patients who did not receive anti-osteoporosis medication both 6 months and 1 year after fracture treatment. Patients who did not receive the medication 1 year after their treatment were enrolled and interviewed using a no-treatment questionnaire. RESULTS In total, 530 patients with fragility hip fractures were eligible (mean age, 79.0 years), and most (74.5%) were women. Only 148 patients (31.6%) received anti-osteoporosis medication 1 year after hip fracture. Logistic regression analysis identified predictors for not receiving the medication: male sex (OR 1.8; 95% CI 1.1-3.0), Charlson comorbidity index score ≥ 5 (OR 1.5; 95% CI 1.0-2.3), and secondary school education or below (OR 2.0; 95% CI 1.2-3.3). The main reason for not receiving the medication was that healthcare providers neither discussed nor initiated pharmacological treatment for osteoporosis (48.2%). When the medication was prescribed, non-persistence primarily stemmed from transportation difficulties that resulted in patients missing follow-ups (50.0%). CONCLUSIONS Improved physician attitudes toward anti-osteoporosis medications might enhance the treatment rate. Developing a follow-up team and facilitating access to medications (eg, courier delivery to patients) would promote therapy compliance. TRIAL REGISTRATIONS The protocol for the first phase and second phase was approved by the Siriraj Institutional Review Board of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (COA no. Si 180/2021) and for the second phase, patients-informed consent forms used in the cross-sectional component were approved by the Siriraj Institutional Review Board of the Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand (COA no. Si 180/2021). The research was registered with the Thai Clinical Trials Registry (TCTR number: 20210824002). The study was conducted in accordance with the Declaration of Helsinki. Each patient (or a relative/caregiver) provided informed consent in writing or by telephone to participate in this second study phase.
Collapse
Affiliation(s)
- Chantas Mahaisavariya
- grid.10223.320000 0004 1937 0490Golden Jubilee Medical Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand
| | - Ekasame Vanitcharoenkul
- grid.10223.320000 0004 1937 0490Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700 Thailand
| | - Nitchanant Kitcharanant
- grid.7132.70000 0000 9039 7662Department of Orthopaedics, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand
| | - Pojchong Chotiyarnwong
- grid.10223.320000 0004 1937 0490Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700 Thailand
| | - Aasis Unnanuntana
- Department of Orthopaedic Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, 2 Wanglang Road, Bangkoknoi, Bangkok, 10700, Thailand.
| |
Collapse
|
3
|
Larsen SB, Dehlendorff C, Skriver C, Pottegård A, Friis S, Røder MA, Brasso K, Duun-Henriksen AK. Prescription rates for commonly used drugs before and after a prostate cancer diagnosis. Cancer Causes Control 2022; 33:417-428. [PMID: 35006514 DOI: 10.1007/s10552-021-01537-8] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2021] [Accepted: 12/10/2021] [Indexed: 01/01/2023]
Abstract
PURPOSE To investigate differences in prescription rates of commonly used drugs among prostate cancer patients and cancer-free comparisons and between patients diagnosed with localized and non-localized disease. METHODS We conducted a register-based study including all men aged 50-85 years diagnosed with prostate cancer in Denmark from 1998 to 2015 and an age-matched cancer-free comparison cohort. We calculated the number of new and total prescriptions from three years before to three years after the date of diagnosis of the case for selected drug classes divided by the number of person-months and stratified by stage at diagnosis. RESULTS We included 54,286 prostate cancer patients and 249,645 matched comparisons. 30,712 patients were diagnosed with localized disease and 12,884 with non-localized disease. The rates of new prescriptions increased considerably among patients within the year before the diagnosis. Hereafter the rates varied between drug classes. For most drug classes, total prescription rates for patients and comparisons increased similarly in the study period. Total prescription rates varied between men with localized and non-localized disease for all drug classes apart from statins. CONCLUSION Our findings indicate that a large proportion of prostate cancer cases are likely diagnosed during medical work-up for other reasons than prostate cancer. Increased rates occur within the last year before diagnosis and future studies on the interaction between drug use and prostate cancer should at least include a one year pre-diagnostic lag-time. Post-diagnostic prescription rates demonstrated an increased use of drugs most likely associated with the consequences of the disease.
Collapse
Affiliation(s)
- Signe Benzon Larsen
- Urological Research Unit, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark.
- Survivorship and Inequality in Cancer, Danish Cancer Society Research Center, Copenhagen, Denmark.
| | - Christian Dehlendorff
- Statistics and Data Analysis, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark
| | - Charlotte Skriver
- Cancer Surveillance and Pharmacoepidemiology, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark
| | - Anton Pottegård
- Clinical Pharmacology and Pharmacy, Department of Public Health, University of Southern Denmark, Odense, Denmark
| | - Søren Friis
- Cancer Surveillance and Pharmacoepidemiology, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark
| | - Martin Andreas Røder
- Urological Research Unit, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Klaus Brasso
- Urological Research Unit, Department of Urology, Copenhagen University Hospital - Rigshospitalet, Copenhagen, Denmark
- Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Anne Katrine Duun-Henriksen
- Statistics and Data Analysis, Danish Cancer Society Research Center, Danish Cancer Society, Copenhagen, Denmark
| |
Collapse
|
4
|
Han KT, Choi DW, Kim S. Regional and income disparities in treatment and drug adherence of patients with dyslipidemia: a retrospective cohort study in South Korea, 2003-2015. BMC Geriatr 2021; 21:585. [PMID: 34674649 PMCID: PMC8529775 DOI: 10.1186/s12877-021-02510-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2021] [Accepted: 10/01/2021] [Indexed: 11/25/2022] Open
Abstract
Backgrounds Health disparities represent a major public health problem that needs to be addressed, and a variety of factors, including geographical location and income, can contribute to these disparities. Although previous studies have suggested that health differs by region and income, evidence on the difference in treatment rate is relatively insufficient. To identify differences in prescription rates by region and income in patients with dyslipidemia. Methods Using data from the National Health Insurance Service senior cohort, we included older adults who were diagnosed with dyslipidemia in Korea from 2003 to 2015. Overall prescription rate was determined for patients with dyslipidemia. In addition, medication possession ratio and a defined daily dose were analyzed in patients who were prescribed statins. A generalized estimating equation Poisson model was used to assess differences in prescription rates. Results Patients living in rural areas (Chungcheong-do, Jeolla-do, and Gyeongsang-do) had a significantly higher prescription rate than those in metropolitan cities. Unlike the prescription rate, the drug adherence was significantly higher in Seoul, Gyeonggi-do, and Gangwon-do but lower in Jeolla-do and Gyeongsang-do than in metropolitan cities. Patients with low income had lower prescription rates than those with high income, but this difference was not statistically significant. Conclusion Our findings demonstrate differences in the treatment rates of patients with dyslipidemia by region and income. Appropriate interventions are needed in vulnerable regions and groups to increase the treatment rate for patients with dyslipidemia. Supplementary Information The online version contains supplementary material available at 10.1186/s12877-021-02510-5.
Collapse
Affiliation(s)
- Kyu-Tae Han
- Division of Cancer Control and Policy, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, 10408, Republic of Korea
| | - Dong-Woo Choi
- Cancer Data Center, National Cancer Center, 323 Ilsan-ro, Ilsandong-gu, Goyang-si, 10408, Republic of Korea
| | - Seungju Kim
- Department of Nursing, College of Nursing, The Catholic University of Korea, 222, Banpo-daero, Seocho-gu, Seoul, 06591, Republic of Korea.
| |
Collapse
|
5
|
Proietti M, Antoniazzi S, Monzani V, Santalucia P, Franchi C, Fenoglio LM, Melchio R, Fabris F, Sartori MT, Manfredini R, De Giorgi A, Fabbian F, Biolo G, Zanetti M, Altamura N, Sabbà C, Suppressa P, Bandiera F, Usai C, Murialdo G, Fezza F, Marra A, Castelli F, Cattaneo F, Beccati V, di Minno G, Tufano A, Contaldi P, Lupattelli G, Bianconi V, Cappellini D, Hu C, Minonzio F, Fargion S, Burdick L, Francione P, Peyvandi F, Rossio R, Colombo G, Monzani V, Ceriani G, Lucchi T, Brignolo B, Manfellotto D, Caridi I, Corazza GR, Miceli E, Padula D, Fraternale G, Guasti L, Squizzato A, Maresca A, Liberato NL, Tognin T, Rozzini R, Bellucci FB, Muscaritoli M, Molfino A, Petrillo E, Dore M, Mete F, Gino M, Franceschi F, Gabrielli M, Perticone F, Perticone M, Bertolotti M, Mussi C, Borghi C, Strocchi E, Durazzo M, Fornengo P, Dallegri F, Ottonello LC, Salam K, Caserza L, Barbagallo M, Di Bella G, Annoni G, Bruni AA, Odetti P, Nencioni A, Monacelli F, Napolitano A, Brucato A, Valenti A, Castellino P, Zanoli L, Mazzeo M. Use of oral anticoagulant drugs in older patients with atrial fibrillation in internal medicine wards. Eur J Intern Med 2018; 52:e12-e14. [PMID: 29657108 DOI: 10.1016/j.ejim.2018.04.006] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/03/2018] [Revised: 04/05/2018] [Accepted: 04/06/2018] [Indexed: 11/25/2022]
Affiliation(s)
- Marco Proietti
- Department of Neuroscience, Laboratory of Quality Assessment of Geriatric Therapies and Services, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy; Institute of Cardiovascular Sciences, University of Birmingham, Birmingham, United Kingdom
| | - Stefania Antoniazzi
- Scientific Direction, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; Department of Biomedical and Clinical Sciences, Clinical Pharmacology Unit, ASST Fatebenefratelli - Sacco University Hospital, University of Milan, Milan, Italy
| | - Valter Monzani
- Department of Emergency Medicine, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, Milan, Italy
| | - Paola Santalucia
- Scientific Direction, Foundation IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, Italy; IRCCS Centro Neurolesi Bonino Pulejo - Ospedale Piemonte, Messina, Italy
| | - Carlotta Franchi
- Unit of Pharmacoepidemiological Research in Older People, IRCCS - Istituto di Ricerche Farmacologiche "Mario Negri", Milan, Italy.
| | - Luigi M Fenoglio
- Azienda Ospedaliera Santa Croce e Carle di Cuneo - Medicina Interna, Italy
| | - Remo Melchio
- Azienda Ospedaliera Santa Croce e Carle di Cuneo - Medicina Interna, Italy
| | - Fabrizio Fabris
- Azienda Ospedaliera Universitaria di Padova - Clinica Medica I, Italy
| | | | - Roberto Manfredini
- Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale S. Anna - Clinica Medica, Italy
| | - Alfredo De Giorgi
- Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale S. Anna - Clinica Medica, Italy
| | - Fabio Fabbian
- Azienda Ospedaliero-Universitaria di Ferrara - Arcispedale S. Anna - Clinica Medica, Italy
| | - Gianni Biolo
- Azienda Sanitaria Universitaria Integrata di Trieste, Ospedale di Cattinara - Clinica Medica, Italy
| | - Michela Zanetti
- Azienda Sanitaria Universitaria Integrata di Trieste, Ospedale di Cattinara - Clinica Medica, Italy
| | - Nicola Altamura
- Azienda Sanitaria Universitaria Integrata di Trieste, Ospedale di Cattinara - Clinica Medica, Italy
| | - Carlo Sabbà
- Azienda Ospedaliero-Universitaria Policlinico di Bari - Medicina Interna, Italy
| | - Patrizia Suppressa
- Azienda Ospedaliero-Universitaria Policlinico di Bari - Medicina Interna, Italy
| | | | - Carlo Usai
- Azienda Ospedaliero-Universitaria di Sassari - Medicina Interna, Italy
| | - Giovanni Murialdo
- Ospedale Policlinico San Martino, Genova - Clinica di Medicina Interna 2, Italy
| | - Francesca Fezza
- Ospedale Policlinico San Martino, Genova - Clinica di Medicina Interna 2, Italy
| | - Alessio Marra
- Ospedale Policlinico San Martino, Genova - Clinica di Medicina Interna 2, Italy
| | - Francesca Castelli
- Ospedale Policlinico San Martino, Genova - Clinica di Medicina Interna 2, Italy
| | - Federico Cattaneo
- Ospedale Policlinico San Martino, Genova - Clinica di Medicina Interna 2, Italy
| | - Valentina Beccati
- Ospedale Policlinico San Martino, Genova - Clinica di Medicina Interna 2, Italy
| | - Giovanni di Minno
- Azienda Ospedaliera Universitaria Federico II di Napoli - Medicina Interna, Italy
| | - Antonella Tufano
- Azienda Ospedaliera Universitaria Federico II di Napoli - Medicina Interna, Italy
| | - Paola Contaldi
- Azienda Ospedaliera Universitaria Federico II di Napoli - Medicina Interna, Italy
| | - Graziana Lupattelli
- Ospedale "Santa Maria della Misericordia", S. Andrea delle Fratte di Perugia - Medicina Interna, Italy
| | - Vanessa Bianconi
- Ospedale "Santa Maria della Misericordia", S. Andrea delle Fratte di Perugia - Medicina Interna, Italy
| | - Domenica Cappellini
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Medicina Interna, Italy
| | - Cinzia Hu
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Medicina Interna, Italy
| | - Francesca Minonzio
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Medicina Interna, Italy
| | - Silvia Fargion
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Medicina Interna ad Indirizzo Metabolico, Italy
| | - Larry Burdick
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Medicina Interna ad Indirizzo Metabolico, Italy
| | - Paolo Francione
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Medicina Interna ad Indirizzo Metabolico, Italy
| | - Flora Peyvandi
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Ematologia non tumorale e Coagulopatie, Italy
| | - Raffaella Rossio
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Ematologia non tumorale e Coagulopatie, Italy
| | - Giulia Colombo
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Ematologia non tumorale e Coagulopatie, Italy
| | - Valter Monzani
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Medicina Interna ad Alta Intensità Di Cura, Italy
| | - Giuliana Ceriani
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Medicina Interna ad Alta Intensità Di Cura, Italy.
| | - Tiziano Lucchi
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Geriatria, Italy
| | - Barbara Brignolo
- Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico di Milano - Geriatria, Italy
| | - Dario Manfellotto
- Ospedale San Giovanni Calibita Fatebenefratelli di Roma - Medicina Interna, Italy
| | - Irene Caridi
- Ospedale San Giovanni Calibita Fatebenefratelli di Roma - Medicina Interna, Italy
| | | | - Emanuela Miceli
- IRCCS Fondazione Policlinico San Matteo di Pavia - Clinica Medica I, Italy
| | - Donatella Padula
- IRCCS Fondazione Policlinico San Matteo di Pavia - Clinica Medica I, Italy
| | - Giacomo Fraternale
- IRCCS Fondazione Policlinico San Matteo di Pavia - Clinica Medica I, Italy
| | - Luigina Guasti
- Ospedale di Circolo e Fondazione Macchi, Azienda Socio-Sanitaria Territoriale Sette-Laghi, Varese, Università degli Studi dell'Insubria Varese - Medicina Interna 1, Italy
| | - Alessandro Squizzato
- Ospedale di Circolo e Fondazione Macchi, Azienda Socio-Sanitaria Territoriale Sette-Laghi, Varese, Università degli Studi dell'Insubria Varese - Medicina Interna 1, Italy
| | - Andrea Maresca
- Ospedale di Circolo e Fondazione Macchi, Azienda Socio-Sanitaria Territoriale Sette-Laghi, Varese, Università degli Studi dell'Insubria Varese - Medicina Interna 1, Italy
| | - Nicola Lucio Liberato
- Azienda Socio-Sanitaria Territoriale di Pavia Ospedale Civile "C. Mira" di Casorate Primo - Medicina Interna, Italy
| | - Tiziana Tognin
- Azienda Socio-Sanitaria Territoriale di Pavia Ospedale Civile "C. Mira" di Casorate Primo - Medicina Interna, Italy
| | - Renzo Rozzini
- Fondazione Poliambulanza Istituto Ospedaliero di Brescia - Geriatria, Italy
| | | | - Maurizio Muscaritoli
- Dipartimento di Medicina Clinica, Sapienza Università di Roma, Policlinico Umberto I di Roma - Medicina Interna e Nutrizione Clinica, Italy
| | - Alessio Molfino
- Dipartimento di Medicina Clinica, Sapienza Università di Roma, Policlinico Umberto I di Roma - Medicina Interna e Nutrizione Clinica, Italy
| | - Enrico Petrillo
- Dipartimento di Medicina Clinica, Sapienza Università di Roma, Policlinico Umberto I di Roma - Medicina Interna e Nutrizione Clinica, Italy
| | - Maurizio Dore
- Ospedale degli Infermi Di Rivoli - Medicina Generale, Italy
| | - Francesca Mete
- Ospedale degli Infermi Di Rivoli - Medicina Generale, Italy
| | - Miriam Gino
- Ospedale degli Infermi Di Rivoli - Medicina Generale, Italy
| | - Francesco Franceschi
- Fondazione Policlinico Universitario "Agostino Gemelli" di Roma - Medicina D'Urgenza e Pronto Soccorso, Italy
| | - Maurizio Gabrielli
- Fondazione Policlinico Universitario "Agostino Gemelli" di Roma - Medicina D'Urgenza e Pronto Soccorso, Italy
| | - Francesco Perticone
- Azienda Ospedaliero Universitaria "Mater Domini" di Catanzaro - Geriatria, Italy
| | - Maria Perticone
- Azienda Ospedaliero Universitaria "Mater Domini" di Catanzaro - Geriatria, Italy
| | - Marco Bertolotti
- Nuovo Ospedale Civile S. Agostino Estense di Modena - Geriatria e Post-Acuzie Geriatria, Italy
| | - Chiara Mussi
- Nuovo Ospedale Civile S. Agostino Estense di Modena - Geriatria e Post-Acuzie Geriatria, Italy
| | - Claudio Borghi
- Azienda Ospedaliero Universitaria - Policlinico S.Orsola-Malpighi di Bologna - Medicina Interna, Italy
| | - Enrico Strocchi
- Azienda Ospedaliero Universitaria - Policlinico S.Orsola-Malpighi di Bologna - Medicina Interna, Italy
| | - Marilena Durazzo
- Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino - Presidio Molinette, Medicina Interna 3, Italy
| | - Paolo Fornengo
- Azienda Ospedaliero-Universitaria Città della Salute e della Scienza di Torino - Presidio Molinette, Medicina Interna 3, Italy
| | - Franco Dallegri
- Ospedale Policlinico San Martino, Genova - Medicina Interna, Italy
| | | | - Kassem Salam
- Ospedale Policlinico San Martino, Genova - Medicina Interna, Italy
| | - Lara Caserza
- Ospedale Policlinico San Martino, Genova - Medicina Interna, Italy
| | - Mario Barbagallo
- Azienda Ospedaliera Universitaria Policlinico P. Giaccone di Palermo - Geriatria, Italy
| | - Giovanna Di Bella
- Azienda Ospedaliera Universitaria Policlinico P. Giaccone di Palermo - Geriatria, Italy
| | - Giorgio Annoni
- Ospedale S.Gerardo di Monza, Azienda Socio-Sanitaria Territoriale di Monza, Clinica Geriatrica Università degli Studi di Milano-Bicocca - Clinica Geriatrica, Italy
| | - Adriana Antonella Bruni
- Ospedale S.Gerardo di Monza, Azienda Socio-Sanitaria Territoriale di Monza, Clinica Geriatrica Università degli Studi di Milano-Bicocca - Clinica Geriatrica, Italy
| | - Patrizio Odetti
- Ospedale Policlinico San Martino, Genova - Clinica Geriatrica, Italy
| | - Alessio Nencioni
- Ospedale Policlinico San Martino, Genova - Clinica Geriatrica, Italy
| | | | | | - Antonio Brucato
- Ospedale Papa Giovanni XXIII di Bergamo - Medicina Interna, Italy
| | - Anna Valenti
- Ospedale Papa Giovanni XXIII di Bergamo - Medicina Interna, Italy
| | - Pietro Castellino
- Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele" di Catania - Medicina Interna, Italy
| | - Luca Zanoli
- Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele" di Catania - Medicina Interna, Italy
| | - Marco Mazzeo
- Azienda Ospedaliero-Universitaria "Policlinico-Vittorio Emanuele" di Catania - Medicina Interna, Italy
| |
Collapse
|
6
|
Zaitsu M, Yoo BK, Tomio J, Nakamura F, Toyokawa S, Kobayashi Y. Impact of a direct-to-consumer information campaign on prescription patterns for overactive bladder. BMC Health Serv Res 2018; 18:325. [PMID: 29724205 PMCID: PMC5934904 DOI: 10.1186/s12913-018-3147-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2017] [Accepted: 04/25/2018] [Indexed: 11/15/2022] Open
Abstract
Background Direct-to-consumer information (DTCI) campaign is a new medium to inform and empower patients in their decision-making without directly promoting specific drugs. However, little is known about the impact of DTCI campaigns, expanding rapidly in developed countries, on changes in prescription patterns. We sought to determine whether a DTCI campaign on overactive bladder increases the prescription rate for overactive bladder treatment drugs. Methods We performed a 3-year retrospective cohort study of 1332 participants who were diagnosed overactive bladder but not prescribed treatment drugs prior to the examined DTCI campaign (exposure), using the health insurance claims dataset of the Japan Medical Data Center (November 19, 2010 to November 18, 2013). The DTCI campaign for overactive bladder included television, Internet, and print advertising (November 19, 2011 to December 22, 2011). We divided the study period into Pre-Campaign Year (2010–2011), Year 1 (2011–2012), and Year 2 (2012–2013). Each year began on November 19 and included Period 1 (weeks 1–5) through Period 10 (weeks 46–50). The main outcome was first-time prescription of the treatment drug for each patient, measured by 5-week periods. Using Period 10 in the Pre-Campaign Year as the referent period, we applied the Cox proportional hazard model for each period. Additionally, we performed the interrupted time series analysis (ITSA) for the first-time prescription rate per 5-week period. Results Following the DTCI campaign, patients were about seven times more likely to receive a first prescription of a treatment drug during Period 4 in Year 1 (hazard ratio 7.09; 95% CI, 2.11–23.8; p-value<.01) compared with the reference period. Similar increases were also observed for subsequent Periods 5 and 6 in Year 1. The ITSA confirmed the DTCI campaign impact on the level of prescription rate (one-time increase in the regression-intercept) that increased by 1128.1 [per standardized 100,000 persons] (p < .05) during Period 4 in Year 1. Conclusions The examined DTCI campaign appeared to increase the prescription rate among patients with overactive bladder for 15 weeks with a 15-week delay. Clinical outcomes of the patients with targeted diseases need to be monitored after DTCI campaigns by a future study. Electronic supplementary material The online version of this article (10.1186/s12913-018-3147-1) contains supplementary material, which is available to authorized users.
Collapse
Affiliation(s)
- Masayoshi Zaitsu
- Department of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan. .,Department of Social and Behavioral Sciences, Harvard T.H. Chan School of Public Health, 677 Huntington Avenue, Kresge Building, 7th Floor, Boston, MA, 02215, USA.
| | - Byung-Kwang Yoo
- Department of Public Health Sciences, University of California, Davis, One Shields Avenue, Medical Sciences 1-C, Davis, CA, 95616, USA
| | - Jun Tomio
- Department of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
| | - Fumiaki Nakamura
- Department of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
| | - Satoshi Toyokawa
- Department of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
| | - Yasuki Kobayashi
- Department of Public Health, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-0033, Japan
| |
Collapse
|
7
|
Shipton EE, Shipton AJ, Williman JA, Shipton EA. Deaths from Opioid Overdosing: Implications of Coroners' Inquest Reports 2008-2012 and Annual Rise in Opioid Prescription Rates: A Population-Based Cohort Study. Pain Ther 2017; 6:203-215. [PMID: 28887789 PMCID: PMC5693811 DOI: 10.1007/s40122-017-0080-7] [Citation(s) in RCA: 28] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/12/2017] [Indexed: 12/19/2022] Open
Abstract
INTRODUCTION In the late 1990s multiple physicians and advocacy organizations promoted increased use of opioids for the treatment of acute, chronic and cancer pain. There has been an exponential growth in opioid prescribing in the last 20 years in the United States of America, in Australia, and in other developed Western countries. There are negative consequences associated with the liberal use of opioids. The primary aim of this population-based cohort study is to investigate the opioid-related death rate in New Zealand between 1 January 2008 and 31 December 2012. The secondary aims of this cohort study are: (1) to compare the opioid-related death rate per population in New Zealand in 2001/2002 with that between 2011/2012; (2) to investigate the number of opioid prescriptions in New Zealand between 2001 and 2012; (3) to compare the opioid-related death rate per population in New Zealand between 2001 and 2012 with the number of opioid prescriptions in New Zealand between 2001 and 2012. METHODS Permission to access records from the Coronial Services Office in Wellington for 2008-2012 was acquired. Permission to access records for prescriptions containing opioids (dose and formulation) was obtained from the Pharmaceutical Collection. RESULTS The rate of opioid-related deaths in New Zealand has increased by 33% from 2001 to 2012. More than half of the opioid-related deaths between 2008 and 2012 were unintentional opioid overdoses. Opioid analgesic deaths were most likely due to methadone, morphine and codeine prescribed by healthcare professionals. That 179 of these opioid-related deaths between 2008 and 2012 were unintentional opioid overdoses, and thus could have been avoided, is tragic. This study shows that there was a steady annual increases in opioid prescriptions in New Zealand from 2001 to 2012. This rise in opioid analgesic deaths was associated with the increases in the numbers of opioid prescriptions. CONCLUSION A multifaceted national public health approach is needed to bring together the various stakeholders involved with pain management, opioid dependence, opioid availability and opioid diversion. There needs to be a targeted approach to educate current and future medical practitioners regarding the appropriate use of opioid prescriptions for the management of pain, as well as a strengthening of primary, secondary and tertiary resources to support medical practitioners managing their patients who suffer with pain.
Collapse
Affiliation(s)
- Elspeth E Shipton
- Department of Anaesthesia, University of Otago, Christchurch, New Zealand
| | - Ashleigh J Shipton
- Department of Anaesthesia, University of Otago, Christchurch, New Zealand
| | - Jonathan A Williman
- Department of Population Health, University of Otago, Christchurch, New Zealand
| | - Edward A Shipton
- Department of Anaesthesia, University of Otago, Christchurch, New Zealand.
| |
Collapse
|